English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/168395
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia

AuthorsGonzález-Gascón y Marín, Isabel; Hernández-Sánchez, María; Rodríguez-Vicente, Ana Eugenia; Sanzo, Carmen; Aventín, Anna; Puiggros, Anna; Collado, Rosa; Heras, Cecilia; Muñoz-Novas, Carolina; Delgado, Julio; Ortega, Margarita; González, María-Teresa; Marugán, Isabel; Fuente, Ignacio de la; Recio, Isabel; Bosch, Francesc; Espinet, Blanca; González, Marcos ; Hernández, Jesús M. ; Hernández, José Ángel
KeywordsChronic lymphocytic leukemia
Issue Date2016
PublisherJohn Wiley & Sons
CitationHematological Oncology 34(2): 84-92 (2016)
AbstractThe prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients diagnosed with CLL carrying +12. Median OS was 129 months. One hundred seventy-four patients (60.2%) presented +12 in <60% of cells. TTFT and OS for this subgroup were longer than for the subgroup with +12 in ≥60% of cells, with a median TTFT of 49 months (CI95%, 39–58) vs 30 months (CI95%, 22–38) (P = 0.001); and a median OS of 159 months (CI95%, 119–182), vs 96 months (CI95%, 58–134) (P = 0.015). Other factors associated with a shorter TTFT were: Binet stage, B symptoms, lymphadenopathy, splenomegaly, high lymphocyte count, 11q-, high βmicroglobulin, and high LDH. In the multivariate analysis, clinical stage, +12 in ≥60% of cells, high lymphocyte count, B symptoms, and 11q- in addition, resulted of significance in predicting shorter TTFT. Significant variables for OS were: Binet stage, lymphadenopathy, splenomegaly, high LDH, high βmicroglobulin, 11q-, and CD38. In the multivariate analysis, only Binet stage, 11q-, and high β2microglobulin significantly predicted shorter OS. CLL with +12 entails a heterogeneous group with intermediate prognosis. However, a high proportion of cells carrying +12 separates a subgroup of patients with poor outcome.
DescriptionOn behalf of Grupo Español de Leucemia Linfática Crónica (GELLC), Grupo Cooperativo Español de Citogenética Hematológica (GCECGH).
Identifiersdoi: 10.1002/hon.2196
e-issn: 1099-1069
issn: 0278-0232
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.